The use of biomarkers in detecting subclinical cardiotoxicity in doxorubicin-based treatment for paediatric patients with acute lymphoblastic leukaemia

Radu, Letiţia Elena; Beldiman, Andra; Ghiorghiu, Ioana; Oprescu, Alina; C, Arion; Coliţă, Anca

doi:10.1515/rrlm-2017-0014

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In opposition, there are studies which contradict the usefulness of these markers and support the hypothesis that the variations are due to physiological changes or underlying cardiovascular conditions (8). Moreover, several studies have shown that troponin was not useful for the assessment of CIC after 1-2 years following chemotherapy (12). Soker In the paper authored by Tian S., reference is made to four studies conducted on breast cancer patients, treated with AC, where the correlation between troponin I and LVEF was analyzed (35).…”

Section: Biomarkers Used In Diagnosing Cicmentioning

confidence: 99%

“…The first documentation of cardiotoxicity in ALL patients was in 1967 (11). AC are known to cause irreversible and dose-dependent cardiac impairment, translated into subclinical dysfunction, arrhythmias, cardiomyopathy, and congestive heart failure (12). There are studies showing patients with partial remission of this injury, probably due to early detection (13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia

Radu

Sfetea

et al. 2020

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Acute lymphoblastic leukemia is the most common hematological malignancy at pediatric age. Cardiotoxicity holds the first place among the causes of morbidity and mortality in these patients. Anthracyclines are cytostatic drugs frequently associated with cardiotoxicity. Early diagnosis of cardiac impairment during the treatment of pediatric patients is extremely important, both for modulating future chemotherapy and for administering cardioprotective agents. Long term monitoring after chemotherapy helps to identify the risk of late cardiotoxicity among cancer survivors. There are several biomarkers, already in use or still under study, which may represent an operator-independent alternative for echocardiography in the diagnosis of cardiotoxicity. In case of cardiac damage, the clinician has options for treating or limiting the progression, either with the use of already approved agents, such as Dexrazoxane, or by administrating other cardioprotective drugs. International experts are still attempting to establish the best algorithm for early detection of cardiotoxicity, as well as the most efficient treatment plan in case of already existing myocardial damage in these patients. We present a review on treatment-related cardiotoxicity, including mechanisms of development, useful biomarkers and treatment options, after carefully analyzing specialty literature.

show abstract

Section: Biomarkers Used In Diagnosing Cicmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia

Radu

Sfetea

et al. 2020

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…Acute leukemia represents 25-30% of all pediatric neoplasms and acute lymphoblastic leukemia (ALL) comprises 80% of cases [1]. At present, the overall sur-vival rates of ALL patients are between 80-90% [2], being the most successful story of modern multi-agent chemotherapy [3].…”

Section: Introductionmentioning

confidence: 99%

Cardiotoxicity evaluation in pediatric patients with acute lymphoblastic leukemia – results of prospective study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Aim: The chemotherapy protocol for acute lymphoblastic leukemia (ALL) uses low doses of anthracyclines (AC), generally associated with subclinical cardiotoxicity. The aim of our study was to evaluate the serum biomarkers and echocardiography parameters in children with ALL treated with AC in order to determine the most useful element for early detection of cardiotoxicity.Material and methods: In this prospective study, troponin I (TnI) and heart-type fatty acid binding protein (HFABP) were assessed five times during the first year after the onset of ALL. Serial Tissue Doppler Imaging and conventional cardiac echography were performed by two pediatric cardiologists (intraclass correlation coefficient over 0.85 for all measurements) in three periods during the study protocol.Results: We evaluated 48 children with ALL. TnI increased during therapy, without returning to baseline values one year after diagnosis. HFABP did not show significant changes during the study protocol. Left ventricle outflow tract time-velocity integral and peak systolic septal mitral annulus velocity decreased during chemotherapy and returned to baseline levels at one year after diagnosis, while peak systolic tricuspid annulus velocity and excursion, maintained a descending tendency. Early filling transmitral flow velocity and E/A ratio were also transiently influenced by chemotherapy.Conclusions: The study showed signs of transient cardiotoxicity in the left ventricle and diastolic parameters after chemotherapy, compared to right ventricle parameters which maintained low values even one year after diagnosis. TnI proved to be directly proportional to chemotherapy doses but HFABP was not useful in this setting

show abstract

The use of biomarkers in detecting subclinical cardiotoxicity in doxorubicin-based treatment for paediatric patients with acute lymphoblastic leukaemia

Abstract: The international standard protocol for acute lymphoblastic leukaemia (ALL)

Cited by 2 publications

References 12 publications

Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia

Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia

Cardiotoxicity evaluation in pediatric patients with acute lymphoblastic leukemia – results of prospective study

Contact Info

Product

Resources

About